Oncology & Cancer

Study finds new pathway for potential glioblastoma treatment

A team led by Texas A&M University's College of Veterinary Medicine & Biomedical Sciences' (CVM) researcher Dr. Stephen Safe has discovered a new pathway that may help suppress the development of glioblastoma tumors, one ...

Oncology & Cancer

Existing drug could treat aggressive brain cancer

A research team from the University of Georgia's Regenerative Bioscience Center has found that a compound molecule used for drug delivery of insulin could be used to treat glioblastoma, an aggressive, usually fatal form of ...

Immunology

Delivering immunotherapy directly to brain tumors

A new study gives insight into how immunotherapies, treatments that help the body's immune system fight cancer, might one day be delivered directly to the brain in order to treat brain tumors.

Oncology & Cancer

Tumor-treating fields in glioblastoma: Indication of a benefit

Glioblastoma is an aggressive brain tumor that usually occurs in late adulthood. Just two years after diagnosis, only 13.6 percent of patients are still alive. Standard treatment consists of surgery, followed by radiation ...

Oncology & Cancer

Study identifies new potential target in glioblastoma

Researchers are hopeful that new strategies could emerge for slowing the growth and recurrence of the most common primary brain cancer in adults, glioblastoma, based on the results of a study published today in Cancer Research.

page 1 from 23

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA